

Product datasheet for TL316557

OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

GM2A Human shRNA Plasmid Kit (Locus ID 2760)

Product data:

Product Type: shRNA Plasmids

Product Name: GM2A Human shRNA Plasmid Kit (Locus ID 2760)

Locus ID: 2760

Synonyms: GM2-AP; SAP-3

Vector:pGFP-C-shLenti (TR30023)E. coli Selection:Chloramphenicol (34 ug/ml)

Mammalian Cell Puromycin

Selection:

Format: Lentiviral plasmids

Components: GM2A - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2760).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 000405, NM 001167607, NM 000405.1, NM 000405.2, NM 000405.3, NM 000405.4,

NM 001167607.1, BC009273, BC009273.2, BM834780, NM 001167607.2, NM 000405.5

UniProt ID: P17900

Summary: This gene encodes a small glycolipid transport protein which acts as a substrate specific co-

factor for the lysosomal enzyme beta-hexosaminidase A. Beta-hexosaminidase A, together with GM2 ganglioside activator, catalyzes the degradation of the ganglioside GM2, and other molecules containing terminal N-acetyl hexosamines. Mutations in this gene result in GM2-gangliosidosis type AB or the AB variant of Tay-Sachs disease. Alternative splicing results in

multiple transcript variants. [provided by RefSeq, Nov 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).